This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Jan. 9, 2014 /PRNewswire/ --
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)
("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for cancer, announced today that
Linda Powers, CEO, will present at the Biotech Showcase™ 2014 Conference that is being held in
San Francisco from
January 13-15, 2014.
NW Bio's presentation will take place on
Monday, January 13, at
4:00 p.m. PST in the Mission II Room at the Parc55 Hotel Wyndham, 55 Cyril Magnin St, Union Square. There will be a live audio webcast of the presentation available at
http://nwbio.com/webcasts/. During her presentation, Ms. Powers will provide an overview of the Company's cancer vaccine platform technology, product pipeline and clinical programs with DCVax-L and DCVax-Direct.
If you are interested in meeting with NW Bio's management during the conference, please contact
Lisa Sher of MBS Value Partners at
About Northwest Biotherapeutics
Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio's proprietary manufacturing technology enables the Company to produce its personalized vaccine in an efficient, cost-effective manner. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company's lead product, DCVax-L, is currently in a 312-patient Phase III trial in the U.S. and
Europe for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The Company's second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers. The Company has also conducted a small Phase I/II trial with DCVax for metastatic ovarian cancer together with the
University of Pennsylvania. The Company previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.